Literature DB >> 18782313

The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.

Vincenzo Ficarra1, Giacomo Novara, Antonio Galfano, Matteo Brunelli, Stefano Cavalleri, Guido Martignoni, Walter Artibani.   

Abstract

OBJECTIVE: To compare the prognostic accuracy of the two most used integrated staging systems to predict the outcome of patients with clear cell renal cell carcinoma (RCC). PATIENTS AND METHODS: We retrospectively evaluated the clinical and pathological data of 388 patients surgically treated for clear cell RCC between 1986 and 2000. The pathological slides of all specimens were reviewed by a pathologist unaware of patient outcome. All patients were classified according to the 'Stage, Size, Grade and Necrosis' (SSIGN) score and University of California Los Angeles Integrated Staging System (UISS) model, and the predictive accuracy of the two models was evaluated using receiver operating characteristics (ROC) curves.
RESULTS: The median follow-up was 56 months; the 10-year cancer-specific survival (CSS) probabilities according to the SSIGN score were 96% in the '0-2' category, 78% in the '3-4', 43% in the '5-6', 25.8% in the '7-9' and 0% in the '> or =10' group (P < 0.001). According to the UISS, in nonmetastatic patients the 10-year CSS probabilities were 100% in low, 73% in intermediate and 62% in high-risk groups; in metastatic patients the respective CSS probabilities were 37%, 33% and 12.5% (P < 0.001). The area under the ROC curve (AUC) was 0.870 for the SSIGN score and 0.832 for the UISS. Including only nonmetastatic patients in the analysis, the AUC was 0.830 for the SSIGN score and 0.760 for the UISS model.
CONCLUSION: Our study shows for the first time that the SSIGN score offers a better stratification of clear cell RCC than the UISS model. These data should be considered in the design of future randomized controlled trials.

Entities:  

Mesh:

Year:  2008        PMID: 18782313     DOI: 10.1111/j.1464-410X.2008.07901.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  28 in total

1.  [Current guideline-oriented follow-up of small renal masses : Applied risk scores and future outlook].

Authors:  V Stühler; S Kruck; T Todenhöfer; A Stenzl; J Bedke
Journal:  Urologe A       Date:  2018-03       Impact factor: 0.639

2.  Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.

Authors:  Lucia B Jilaveanu; Maneka Puligandla; Sarah A Weiss; Xin Victoria Wang; Christopher Zito; Keith T Flaherty; Marta Boeke; Veronique Neumeister; Robert L Camp; Adebowale Adeniran; Michael Pins; Judith Manola; Robert S DiPaola; Naomi B Haas; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2017-10-24       Impact factor: 12.531

3.  Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets.

Authors:  Vijay R Dondeti; Bradley Wubbenhorst; Priti Lal; John D Gordan; Kurt D'Andrea; Edward F Attiyeh; M Celeste Simon; Katherine L Nathanson
Journal:  Cancer Res       Date:  2011-11-17       Impact factor: 12.701

4.  Re: Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification. T. Klatte, J. W. Said, M. de Martino, J. Larochelle, B. Shuch, J. Y. Rao, G. V. Thomas, F. F. Kabbinavar, A. S. Belldegrun and A. J. Pantuck. J Urol 2009; 181: 1558-1564.

Authors:  Rodney H Breau; John C Cheville; Christine M Lohse; Eugene D Kwon; Michael L Blute
Journal:  J Urol       Date:  2009-10-21       Impact factor: 7.450

5.  Cannabinoid receptor 2 as a novel target for promotion of renal cell carcinoma prognosis and progression.

Authors:  Jianfeng Wang; Yunze Xu; Liangsong Zhu; Yun Zou; Wen Kong; Baijun Dong; Jiwei Huang; Yonghui Chen; Wei Xue; Yiran Huang; Jin Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2017-10-09       Impact factor: 4.553

6.  Application of the Stage, Size, Grade, and Necrosis (SSIGN) Score for Clear Cell Renal Cell Carcinoma in Contemporary Patients.

Authors:  William P Parker; John C Cheville; Igor Frank; Harras B Zaid; Christine M Lohse; Stephen A Boorjian; Bradley C Leibovich; R Houston Thompson
Journal:  Eur Urol       Date:  2016-06-07       Impact factor: 20.096

7.  Magnetic Resonance Imaging Radiomics Analyses for Prediction of High-Grade Histology and Necrosis in Clear Cell Renal Cell Carcinoma: Preliminary Experience.

Authors:  Durgesh K Dwivedi; Yin Xi; Payal Kapur; Ananth J Madhuranthakam; Matthew A Lewis; Durga Udayakumar; Robert Rasmussen; Qing Yuan; Aditya Bagrodia; Vitaly Margulis; Michael Fulkerson; James Brugarolas; Jeffrey A Cadeddu; Ivan Pedrosa
Journal:  Clin Genitourin Cancer       Date:  2020-05-23       Impact factor: 2.872

Review 8.  Systemic adjuvant therapies in renal cell carcinoma.

Authors:  Sebastiano Buti; Melissa Bersanelli; Maddalena Donini; Andrea Ardizzoni
Journal:  Oncol Rev       Date:  2012-10-08

9.  Adjuvant and neoadjuvant small-molecule targeted therapy in high-risk renal cell carcinoma.

Authors:  A Kapoor; A Gharajeh; A Sheikh; J Pinthus
Journal:  Curr Oncol       Date:  2009-05       Impact factor: 3.677

Review 10.  Adjuvant therapy in renal cell carcinoma-past, present, and future.

Authors:  Tobias Janowitz; Sarah J Welsh; Kamarul Zaki; Peter Mulders; Tim Eisen
Journal:  Semin Oncol       Date:  2013-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.